166 related articles for article (PubMed ID: 37481074)
1. Polygenic risk scores for prediction of cancer-associated venous thromboembolism in the UK Biobank cohort study.
Guman NAM; Mulder FI; Ferwerda B; Zwinderman AH; Kamphuisen PW; Büller HR; van Es N
J Thromb Haemost; 2023 Nov; 21(11):3175-3183. PubMed ID: 37481074
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer.
Guman NAM; van Geffen RJ; Mulder FI; van Haaps TF; Hovsepjan V; Labots M; Cirkel GA; Y F L de Vos F; Ten Tije AJ; Beerepoot LV; Tjan-Heijnen VCG; van Laarhoven HWM; Hamberg P; Vulink AJE; Los M; Zwinderman AH; Ferwerda B; Lolkema MPJK; Steeghs N; Büller HR; Kamphuisen PW; van Es N
J Thromb Haemost; 2021 Dec; 19(12):2974-2983. PubMed ID: 34409743
[TBL] [Abstract][Full Text] [Related]
3. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.
Muñoz A; Ay C; Grilz E; López S; Font C; Pachón V; Castellón V; Martínez-Marín V; Salgado M; Martínez E; Calzas J; Ortega L; Rupérez A; Salas E; Pabinger I; Soria JM
J Clin Oncol; 2023 Jun; 41(16):2911-2925. PubMed ID: 36730884
[TBL] [Abstract][Full Text] [Related]
4. The risk of venous thromboembolism in oral contraceptive users: the role of genetic factors-a prospective cohort study of 240,000 women in the UK Biobank.
Lo Faro V; Johansson T; Johansson Å
Am J Obstet Gynecol; 2024 Mar; 230(3):360.e1-360.e13. PubMed ID: 37734636
[TBL] [Abstract][Full Text] [Related]
5. Risk assessment of venous thromboembolism in inflammatory bowel disease by inherited risk in a population-based incident cohort.
Rifkin AS; Shi Z; Wei J; Zheng SL; Helfand BT; Cordova JS; Biank VF; Tafur AJ; Khan O; Xu J
World J Gastroenterol; 2023 Oct; 29(39):5494-5502. PubMed ID: 37900992
[TBL] [Abstract][Full Text] [Related]
6. Replication of a genetic risk score for venous thromboembolism in whites but not in African Americans.
Folsom AR; Tang W; Weng LC; Roetker NS; Cushman M; Basu S; Pankow JS
J Thromb Haemost; 2016 Jan; 14(1):83-8. PubMed ID: 26565658
[TBL] [Abstract][Full Text] [Related]
7. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer.
Parker A; Peterson E; Lee AYY; de Wit C; Carrier M; Polley G; Tien J; Wu C
J Thromb Haemost; 2018 Jul; 16(7):1321-1326. PubMed ID: 29733498
[TBL] [Abstract][Full Text] [Related]
8. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS).
Pabinger I; Ay C; Dunkler D; Thaler J; Reitter EM; Marosi C; Zielinski C; Mannhalter C
J Thromb Haemost; 2015 Jan; 13(1):17-22. PubMed ID: 25381723
[TBL] [Abstract][Full Text] [Related]
9. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer.
Muñoz Martín AJ; Ortega I; Font C; Pachón V; Castellón V; Martínez-Marín V; Salgado M; Martínez E; Calzas J; Rupérez A; Souto JC; Martín M; Salas E; Soria JM
Br J Cancer; 2018 Apr; 118(8):1056-1061. PubMed ID: 29588512
[TBL] [Abstract][Full Text] [Related]
10. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.
Pelletier R
J Oncol Pharm Pract; 2021 Jun; 27(4):911-918. PubMed ID: 33757321
[TBL] [Abstract][Full Text] [Related]
11. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
Pépin M; Kleinjan A; Hajage D; Büller HR; Di Nisio M; Kamphuisen PW; Salomon L; Veyradier A; Stepanian A; Mahé I
J Thromb Haemost; 2016 Feb; 14(2):306-15. PubMed ID: 26589836
[TBL] [Abstract][Full Text] [Related]
12. Comparison among three predictive models for cancer-associated thromboembolism in a hispanic population.
Ramos-Esquivel A; Marenco-Flores A; Hernández-Romero G; Céspedes-Calvo A; Mora-Hidalgo R
J Thromb Thrombolysis; 2023 Oct; 56(3):433-438. PubMed ID: 37407771
[TBL] [Abstract][Full Text] [Related]
13. Joint effects of prothrombotic genotypes and body height on the risk of venous thromboembolism: the Tromsø study.
Horvei LD; Braekkan SK; Smith EN; Solomon T; Hindberg K; Frazer KA; Rosendaal FR; Hansen JB
J Thromb Haemost; 2018 Jan; 16(1):83-89. PubMed ID: 29094466
[TBL] [Abstract][Full Text] [Related]
14. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer.
Mansfield AS; Tafur AJ; Wang CE; Kourelis TV; Wysokinska EM; Yang P
J Thromb Haemost; 2016 Sep; 14(9):1773-8. PubMed ID: 27273134
[TBL] [Abstract][Full Text] [Related]
15. Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort.
Blix K; Gran OV; Severinsen MT; Cannegieter SC; Jensvoll H; Overvad K; Hammerstrøm J; Tjønneland A; Naess IA; Braekkan SK; Rosendaal FR; Kristensen SR; Hansen JB
J Thromb Haemost; 2018 Jul; 16(7):1327-1335. PubMed ID: 29691978
[TBL] [Abstract][Full Text] [Related]
16. Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data.
Tsubata Y; Kawakado K; Hamai K; Furuya N; Yokoyama T; Saito R; Nakamura A; Masuda T; Hamaguchi M; Kuyama S; Honda R; Senoo T; Nakanishi M; Hotta T; Yamasaki M; Ishikawa N; Fujitaka K; Kubota T; Kobayashi K; Isobe T
Int J Clin Oncol; 2023 Jan; 28(1):69-78. PubMed ID: 36357710
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for cancer-associated venous thromboembolism: The venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study.
Douce DR; Holmes CE; Cushman M; MacLean CD; Ades S; Zakai NA
J Thromb Haemost; 2019 Dec; 17(12):2152-2159. PubMed ID: 31423717
[TBL] [Abstract][Full Text] [Related]
18. Comparison of risk prediction scores for cancer-associated thrombosis in ambulatory cancer patients not receiving thromboprophylaxis: A prospective cohort study in a South-East Asian population.
Thipbumrung S; Niprapan P; Suprasert P; Ketpueak T; Tantiworawit A; Punnachet T; Hantrakun N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Rattarittamrong E; Norasetthada L; Chai-Adisaksopha C
Thromb Res; 2023 Dec; 232():138-144. PubMed ID: 37979462
[TBL] [Abstract][Full Text] [Related]
19. Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study.
Nopp S; Moik F; Kraler S; Englisch C; Preusser M; von Eckardstein A; Pabinger I; Lüscher TF; Ay C
J Thromb Haemost; 2023 Sep; 21(9):2461-2472. PubMed ID: 37192696
[TBL] [Abstract][Full Text] [Related]
20. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts.
Pabinger I; van Es N; Heinze G; Posch F; Riedl J; Reitter EM; Di Nisio M; Cesarman-Maus G; Kraaijpoel N; Zielinski CC; Büller HR; Ay C
Lancet Haematol; 2018 Jul; 5(7):e289-e298. PubMed ID: 29885940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
